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The capsid protein of the human immunodeficiency virus type 1 has been
found to be a substrate of the retroviral protease in vitro, and its process-
ing was predicted to be strongly dependent on a pH-induced conforma-
tional change. Several protease cleavage sites have been identified within
the capsid protein, but the importance of its cleavage by the viral protease
at the early phase of infection is controversial. To confirm the relevance of
this process, we aimed to design, produce, and characterize mutant capsid
proteins, in which the protein susceptibility toward HIV-1 protease is
altered without affecting other steps of the viral life cycle. Our results indi-
cate that while the introduced mutations changed the cleavage rate at the
mutated sites of the capsid protein by HIV-1 protease, some of them
caused only negligible or moderate structural changes (A78V, L189F, and
L189I). However, the effects of other mutations (W23A, A77P, and
L189P) were dramatic, as assessed by secondary structure determination or
cyclophilin A-binding assay. Based on our observations, the L189F mutant
capsid remains structurally and functionally unchanged and may therefore
be the best candidate for use in studies aimed at better understanding the
role of the protease in the early postentry events of viral infection or retro-
virus-mediated gene transduction.
HIV-1 is a member of the retrovirus family and is a
causative agent of acquired immunodeficiency syn-
drome. The advance in highly active antiretroviral
therapy (HAART) had dramatically changed the out-
come of disease progression; however, a definitive cure
is not yet available. The total number of people living
with HIV infection is estimated to be over 36 million
worldwide, according to the 2014 report of UNAIDS
on the global AIDS epidemic. On the other hand,
HIV-based Vesicular stomatitis virus-pseudotyped self-
inactivating vectors are among the most frequently uti-
lized in gene therapy trials.
In mature virions, approximately 1500 capsid (CA)
monomers form a conical structure—called the core—
which contains the viral genome, some viral (nucleo-
capsid, reverse transcriptase, integrase, Vpr, and p6)
and cellular (cyclophilin A, APOBEC3G) proteins,
that introduce the viral genome into target cells [1].
Earlier results strongly suggested that appropriate sta-
bility of the core also had a main role in HIV-1 infec-
tion [2–7] influencing the decapsidation process in the
early phase where the exact identity of the factors
involved is still not fully resolved. Besides the presence
of various viral proteins, the protease (PR) is also part
of the core [8] and, therefore, it might contribute to
the viral infectivity by further processing viral proteins
or by cleaving cellular ones [9]. At the late phase of
the viral life cycle, proteolytic cleavage of Gag and
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Gag-Pol polyproteins is essential for the production of
the mature, infectious virus [10]. In vitro experiment
with the cores of another lentivirus; the equine infec-
tious anemia virus, showed that the viral protease can
cleave the nucleocapsid protein into smaller fragments
[11] leading to the suggestion of an early phase role
for the PR. In previous studies it was established that
proteins of the viral core (CA, NC) are substrates of
the viral protease in vitro [12–14], while other studies
identified over 30 cellular proteins that could be target
of the PR as summarized in Wagner et al. [15]. Never-
theless, PR inhibition studies provided controversial
results, some showing an inhibitory effect on the early
phase [16–19], while others did not find such effect
[20,21]. HIV-1 entry occurs in most cases by direct
fusion, but the endocytotic route could make a sub-
stantial contribution to infectivity depending on the
virus isolate and cell type [22–24]. Although the PR
has been shown to be able to process proteins at the
neutral pH of the cytoplasm, as the pH optimum of
the PR is acidic, the acidic pH of the lysosome is more
favorable for its proteolytic action.
The capsid protein of HIV-1 is composed of 231
amino acid residues, and consists of two independent
domains: an N-terminal core domain (residues 1–145)
[25] and a C-terminal dimerization domain (residues
151–231) [26] that are connected by a short linker region
[27]. The C-terminal domain also contains the evolu-
tionarily conserved major homology region (MHR),
which is crucial for the maintenance of the structure and
interactions with other viral and cellular components
[26]. NMR spectroscopic [25] and X-ray crystallo-
graphic studies [26] revealed that the domain organiza-
tion of the HIV-1 CA protein is highly a-helical.
Moreover, circular dichroism spectroscopic (CD) study
of a recombinant p24 protein (r-p24) showed that under
native conditions, 56% of the protein is folded into
a-helices, 3% into b-sheets, and 20% into turns [28].
Among other viral proteins, the processed CA pro-
tein have also been found to be a substrate for the
retroviral protease in vitro, and its processing is pre-
dicted to be dependent on a pH-induced conforma-
tional change [12]. Based on N-terminal sequencing as
well as MS identification of the fragments of recombi-
nant CA separated by SDS/PAGE, two major CA
cleavage sites were identified: Ala77/Ala78 and
Leu189/Leu190 [12]. In addition to these sites, another
study had identified additional cleavage sites: Ala22/
Trp23, Gly116/Trp117, and Ala204/Leu205 [14]
(Fig. 1). All these cleavage sites are located outside the
MHR region.
Over the past decade, genome-wide siRNA screen-
ings [29,30] and proteomic analyses [31] identified
several cellular proteins which are important for HIV-
1 infection. Some of these factors such as E3 SUMO-
protein ligase (RanBP2), a nuclear pore complex pro-
tein (NUP153), transportin-3 (TNPO3), or the cleav-
age and polyadenylation specificity factor subunit 6
(CPSF6) have been found to be as interaction partners
of the CA protein [32,33]. One of the previously identi-
fied host-derived cofactors, peptidyl-prolyl isomerase
cyclophilin A (CypA) has been shown to be able to
bind the Gag protein of HIV-1 and some other len-
tiviruses [34–36]. CypA has been shown to be incorpo-
rated into HIV-1 virions, and its incorporation was
found to be essential for viral infectivity [37–39], how-
ever, further studies showed that endogenous CypA
present in the target cells is more important for viral
infectivity [40–42]. The CypA binds to the CypA-bind-
ing loop of the CA (87HAGPIA92 in the N-terminal
domain) (Fig. 1). The precise role of CypA in the early
phase of infection is still unclear, binding of CypA to
CA can be inhibited by the drug cyclosporin A (CsA)
or by mutagenesis of the crucial amino acid residues
of the binding regions in either one or both proteins
[35,41]. Both the CsA inhibitor and mutagenesis
impair the infection process in certain cell types, in a
step that exists before or during reverse transcription.
The goal of the present work was based on previous
specificity studies performed by us and others, to select
mutations and introduce them into the major internal
cleavage sites of CA, and to study how these cleavage
site modifications affect the protein structure, impair-
ing or enhancing its proteolytic susceptibility. The aim
was to identify appropriate candidate mutations that
can be used to clarify the potential role of CA process-
ing at the early phase of viral infection, especially in
circumstances when the virus or viral-based vectors are
utilizing the receptor-mediated endocytotic route for
infection, where the pH and the CA structure is more
favorable for the proteolytic processing.
Materials and methods
Mutagenesis, expression, and purification of
recombinant HIV-1 capsid protein
The plasmid bearing the CA protein from HIVIIIB isolate
with an N-terminal 6-his tag (His6-HIVCA) was obtained
from Dr. Carol Carter (Department of Molecular Genetics
and Microbiology, S.U.N.Y. Stony Brook, USA). Muta-
tions were introduced with the QuikChange Site-Directed
Mutagenesis Kit (Stratagene, Agilent Technologies, Santa
Clara, CA, USA), using the mutagenesis primers (Inte-
grated DNA Technologies, Coralville, IA, USA) listed in
Table S1, Supporting Information. The sequences were
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verified by DNA sequencing performed by ABI Prism Dye
Terminator Cycle Sequencing Kit and a model 3100-Avant
Genetic Analyzer (both from Applied Biosystems, Thermo
Fisher Scientific Inc., Waltham, MA, USA). Protein expres-
sion in Escherichia coli BL21(DE3) cells (Invitrogen,
Thermo Fisher Scientific Inc., Waltham, MA, USA) was
induced by the addition of 1 mM IPTG) to the cultures fol-
lowed by incubation at 37 °C for 3 h. Bacterial cells were
suspended in lysis buffer (10 mM Tris-HCl, 150 mM NaCl,
1 mM PMSF, pH 8.0) and then disrupted by sonication.
The insoluble fraction was collected by centrifugation at
17 500 g at 4 °C for 20 min, then washed with the same
buffer and centrifuged again at the same conditions. The
pelleted fraction was resuspended in denaturation buffer
(20 mM NaH2PO4, 500 mM NaCl, 0.1% TritonX-100,
40 mM imidazole, 8 M urea, pH 7.5). After sonication, the
solution was centrifuged at 17 500 g at 4 °C for 25 min,
and then the supernatant was filtered through a 0.22-lm
pore size syringe filter (Merck, Millipore, Darmstadt, Ger-
many) and applied to the Ni-nitrilotriacetic acid Superflow
affinity resin (Qiagen, Hilden, Germany) equilibrated in
CA-binding buffer (20 mM NaH2PO4, 500 mM NaCl, 0.1%
TritonX-100, 40 mM imidazole, pH 7.5). After consecutive,
extensive washing steps using this binding buffer the recom-
binant protein bound to the resin was eluted with CA elu-
tion buffer (20 mM NaH2PO4, 500 mM NaCl, 500 mM
imidazole, pH 7.5). The purified protein was dialyzed over-
night at 4 °C against MQ water, and then concentrated
with a Concentrator plus lyophilizator (Eppendorf, Ham-
burg, Germany). The concentrated protein was fractionated
by gel filtration on Superose 12 10/300 GL column (GE
Healthcare, Little Chalfont, United Kingdom) equilibrated
with equilibraton buffer (50 mM NaH2PO4, 0.15 M NaCl,
pH 7.0), separation was performed at a flow rate of
1 mLmin1 at room temperature. Fractions with the
proper purity were dialyzed and concentrated again with
the same method mentioned above. The concentration of
the clarified proteins were measured based on their A280
values by NanoDrop equipment (Thermo Scientific). The
purity of samples was verified by SDS/PAGE using 16%
polyacrylamide gels.
Construction of pGEX-4T-3-CypA expression
vector
The cyclophilin A coding region was amplified from the PPIA
(NM_021130) human cDNA ORF Clone (Origene, Rock-
ville, MD, USA) using Phusion High-Fidelity DNA polimer-
ase (New England BioLabs, Beverly, MA, USA) with primer
sets 50-GAGGGATCCATGGTCAACCCCACCGTGTTC
TTCG-30 (forward) and 50-GCGACGCGGCCGCAATT
TATTCGAGTTGTCCACAGTCAG-30 (reverse). The for-
ward and reverse primers harbored a recognition sites of
BamHI (underlined) and NotI restriction endonucleases,
respectively. The PCR reaction was performed as it was
described before [43]. After the cleavage of PCR product by
A
C
B
Fig. 1. Structure of wild-type HIV-1 capsid protein and its complex with cyclophilin. (A) Figure shows the ribbon/tube representation of
crystal structures of wild-type HIV-1 capsid protein (3NTE.pdb) (A) and its N-terminal domain bound to cyclophilin A (1AK4.pdb) (B). Residues
harboring the proteolytic cleavage sites are indicated by spacefill representation (residues are labeled by black color), while residues of
cyclophilin A-binding loop (87HAGPIA92) by ball-and-stick representation (residues are labeled by blue color). Color code: red, a-helix; yellow,
b-sheet. (C) Sequence of the wild-type CA. Identified cleavage sites are marked with arrows, and introduced amino acid changes are
indicated with red letters under the wild-type sequence.
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BamHI and NotI, it was ligated into pGEX-4T-3 plasmid
(Addgene, Cambridge, MA, USA).
Expression and purification of CypA-GST fusion
protein
The GST-CypA coding plasmid was transformed into
E. coli BL21(DE3) cells (Invitrogen) and the expression
was induced by the addition of 0.1 mM IPTG to the cul-
tures, and incubated at 37 °C for 3 h. After harvesting the
cells by centrifugation the pellets were treated as described
previously [43]. The clear lysate of cells was then applied to
a Bio-ScaleTM Mini ProfinityTM GST cartridge (BIO-RAD,
Hercules, CA, USA) equilibrated in CypA-binding buffer
(10 mM NaH2PO4, 150 mM NaCl, 5 mM EDTA, pH 7.4).
After consecutive, extensive washing steps with this buffer
the recombinant protein bound to the resin was eluted with
CypA elution buffer (20 mM glutathione, 100 mM Tris-HCl,
5 mM EDTA, pH 8.0). The purified protein was dialyzed
overnight at 4 °C, against MQ water, and then concen-
trated with a lyophilizator. Concentrated proteins were dis-
solved in MQ water again. The concentration of the
clarified proteins were measured based on their A280 values
by a NanoDrop equipment (Thermo Scientific). The purity
of samples was verified by SDS/PAGE using 16%
polyacrylamide gels.
Expression and purification of the recombinant
HIV-1 protease
The construction of HIV-1 PR coding region containing
five stabilizing mutations (Q7K, L33I, L63I, C67A, and
C95A) was described previously [44,45]. The plasmid cod-
ing for this protease was a kind gift of Dr. John M. Louis
(Laboratory of Chemical Physics, NIDDK, NIH).
The HIV-1 PR was expressed in E. coli BL21(DE3) cells
(Invitrogen). Cells were grown at 37 °C up to an absor-
bance of 0.6–0.8 at 600 nm, in Luria–Bertani medium con-
taining 100 lgmL1 ampicillin, and induced for expression
with 1 mM IPTG for 3 h. Cells were harvested by centrifu-
gation at 6000 g at 4 °C for 20 min. After removal of the
supernatant, the cell pellet was treated as described previ-
ously [46]. Briefly, cells were suspended in 20 volume of
buffer A (50 mM Tris, 10 mM EDTA, pH 8.2), and lysed in
the presence of 100 lgmL1 lysosyme by sonication on ice.
The lysate was centrifuged at 20 000 g at 4 °C for 20 min,
the pellet was resuspended in buffer B (buffer A containing
2 M guanidine-HCl and 1% Triton X-100) followed by a
repeated centrifugation. Pelleted inclusion bodies were sus-
pended in buffer A and centrifuged again. The final pellet
was dissolved in buffer C (50 mM Tris, 5 mM EDTA, 7.5 M
guanidine-HCl, pH 8.0) and filtered through 0.22-lm pore
size syringe filter (Millipore). Samples were applied to a
Superose 12 10/300 GL column (GE Healthcare)
equilibrated in buffer D (50 mM Tris, 4 M guanidine-HCl,
5 mM EDTA, pH 8), separation was performed at a flow
rate of 0.5 mLmin1 at room temperature. Peak fractions
were pooled and subjected to reversed-phase HPLC on a
POROS 20 R2 column (Applied Biosystems). Purity of
selected fractions was assessed by SDS/PAGE using 16%
polyacrylamide gels. The protein was folded by dialysis into
0.05 M formic acid at pH 2.8 followed by a dialysis using
0.05 M sodium acetate buffer, pH 5.0. Protein concentra-
tion was measured based on its A280 value by a NanoDrop
equipment (Thermo Scientific).
Prediction of effects of mutations
Secondary structure prediction was performed using
SOPMA secondary structure prediction server [47]. Effects
of the mutations on protein stability were predicted by the
Site Directed Mutator (SDM) server [48] using the crystal
structure of the wild-type full-length HIV-1 capsid protein
(PDB code: 3NTE) [49]. Figures were prepared using Sybyl
program package (Tripos Inc., St. Louis, MO, USA) run
on Silicon Graphics Fuel workstations (Silicon Graphics
International, Fremont, CA, USA).
Circular dichroism spectroscopy
Circular dichroism spectra were recorded on a Jasco-810
spectropolarimeter at room temperature in 10 mM sodium
phosphate buffer (pH 7.5). CD deconvolutions were
obtained using the CDSSTR analysis program [50–52],
kindly provided by Dichroweb [53,54].
Proteolytic digestion of recombinant CA proteins
by HIV-1 protease
Recombinant CA proteins were incubated with PR at PR:
CA ratio of 1:20 at pH 5.5. Reaction mixture containing
recombinant His6-tagged CA protein (10 lM final concentra-
tion) was incubated with recombinant HIV-1 PR (0.5 lM
final concentration) in PR reaction buffer (100 mM sodium
acetate, 1 mM DTT, 1 mM EDTA, 150 mM NaCl, pH 5.5),
as described previously [12]. Briefly, after incubation at
37 °C for 4 h, reactions were stopped by the addition of an
equal volume of 2X tricine-SDS sample buffer containing b-
mercaptoethanol, and by heating at 95 °C for 10 min, and
the samples were analyzed using 16% gradient SDS/PAGE
tricine-buffered gels (Invitrogen). In case of samples ana-
lyzed later by mass spectrometry the reactions were stopped
by the addition of an equal volume of formic acid.
Mass spectrometry
Before the measurements the samples were purified by Zip-
Tip pipette tips loaded by C18 resin (Millipore) to remove
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the salt components of the HIV-1 PR reaction buffer. The
(MALDI-TOF MS) analysis of the CA fragments was per-
formed by a Voyager-DETM PRO MALDI-TOF mass
spectrometer (Applied Biosystems); sinapinic acid was used
as matrix. The instrument was used in the linear mode of
operation.
Limited proteolysis by trypsin
Recombinant CA proteins were incubated with trypsin at
trypsin:CA ratio of 1:100 at pH 7.5 in a reaction buffer as
described previously [55]. Reaction mixtures contained
recombinant his-tagged CA protein (10 lM final concentra-
tion) and trypsin (100 nM final concentration). Samples
were incubated at 37 °C for 2 h, reactions were stopped by
the addition of an 1/6 volume of 6X SDS sample buffer
containing b-mercaptoethanol, and by heating at 95 °C for
10 min. The samples were analyzed using 16% SDS/PAGE
gels.
His6-HIVCA pull-down assay
After binding the His6-HIVCA protein to the Ni-nitrilotri-
acetic acid magnetic agarose beads (Qiagen) at 4 °C for 1 h
using a PBS supplemented with 20 mM imidazole, 0.05%
Tween20, pH 8.0) the mixture was incubated with the puri-
fied GST-CypA protein in PBS at 4 °C for 1 h. The non-
bound material was washed off and the bound complexes
were eluted with a pull-down elution buffer (50 mM
NaH2PO4, 300 mM NaCl, 250 mM imidazole, 0.05%
Tween20, pH 8.0), followed by SDS/PAGE using 14%
polyacrylamide gels.
Statistical analysis
Statistical analysis was performed using GraphPad Quick-
Calcs free web calculator (http://graphpad.com/quickcalcs/
ttest2) (accessed January 2016).
Results
Rationale for the introduced mutations into the
CA protein
Cleavage site mutations were based on the known
specificity features of HIV-1 PR that have been
reviewed previously [56,57]. As both S1- and S10-bind-
ing cavities of HIV-1 PR are large and hydrophobic, it
was predicted that mutation of P10Ala to Val at the
Ala77/Ala78 site as well as P1 Leu to Phe at the
Leu189/Leu190 cleavage site would enhance proteoly-
sis at these sites. On the other hand, mutations of P1
residues to Pro or Ile at these sites were expected to
prevent hydrolysis, as no natural or known artificial
cleavage sites contain these residues at this position.
Besides these mutations, we also studied the Trp23Ala
mutant. The effect of this mutation has been charac-
terized previously, showing enhanced processing of the
CA protein [2]; although the S10-binding cavity of
HIV-1 protease is relatively large, Trp appears to be
too bulky to preferably fit into this site.
Cleavage site mutant HIV-1 capsid proteins
display altered processing profiles
To define the effects of proteolytic cleavage site muta-
tions on the in vitro CA processing, we prepared
mutant capsid proteins in which the P1 (A77P, L189F,
L189I, and L189P mutants) or the P10 (W23A and
A78V mutants) amino acids of the cleavage sites were
replaced. The mutant recombinant CA proteins were
expressed in E. coli and subjected to proteolysis by a
purified recombinant wild-type HIV-1 PR (Fig. 2).
These cleavages were performed at pH 5.5, which is
close to the lysosomal pH as well as to the pH opti-
mum of the HIV-1 PR.
As expected, A77P and L189P amino acid changes
inhibited the proteolytic processing at these sites, as
we have observed a decrease in the product band
intensities or disappearance of the fragments related
to these modified cleavage sites. On the other hand,
the W23A mutation resulted in the accelerated prote-
olytic cleavage of the protein, in good agreement with
previously published results [2]. The modified cleavage
sites became more susceptible to proteolytic cleavage
in the case of A78V and L189F mutants, as indicated
by the increased amount of the related fragments (78–
231 and 1–189, respectively). However, the overall
processing of the L189F CA was reduced, and A78V
CA did not show significant alteration in its prote-
olytic susceptibility compared to that of the wild-type
(Fig. 2). Surprisingly, L189I mutation did not prevent
processing at this site, although P1 Ile has not been
found in HIV-1 cleavage sites. This might be due to a
one-residue shift of the cleavage site to TETIL/
VQNAN to produce a typical type 2 cleavage site
[56,57] for HIV-1 PR, we, however, were unable to
prove this as none of the respective peptides were
recovered in MALDI-TOF experiments (data not
shown).
In silico secondary structure analysis of the
capsid protein
The introduced mutations could potentially alter the
secondary or tertiary structural organization of the
CA protein, in addition to the altered cleavage sites,
5FEBS Open Bio (2016) ª 2016 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
F. Toth et al. Studies on internal HIV-1 capsid cleavage site mutations
the structural alterations could also be responsible for
the observed changes in proteolytic processing.
Effects of mutations on the protein structure were
predicted using the SDM server, which calculates a
stability score analogous to the free energy difference
between a wild-type and mutant protein [48]. The
highest values were predicted for the A77P
(2.27 kcalmol1) and L189P (4.85 kcalmol1)
mutants, which suggested that these mutations have a
highly destabilizing effect on the protein structure and
may potentially cause protein malfunction.
The L189I mutation was predicted to be neutral
(0.37 kcalmol1), while A78V and L189F mutations
were predicted to be slightly destabilizing (1.57 and
0.73 kcalmol1, respectively) and cause only a slight
deviation of the secondary structural organization.
Secondary structure prediction did not predict
changes for W23A mutation, furthermore, SDM server
predicted only slightly destabilizing effect for this
mutation, as well. However, while the introduction of
W23A mutation was predicted to be neutral from the
viewpoint of the conformation of helix I, it was previ-
ously published that this residue is buried in the N-
terminal domain and contributes to the formation of
the hydrophobic core [58]. Therefore, we expected that
W23A mutation would alter both the secondary and
tertiary structure of CA protein, due to its critical role
in stabilization of the protein structure.
M (kDa)
37
25
20
15
10
5
2
– – – – – – – +      +      +      +      +      +       +PR
CA
1 231
1 189
78 231
78 189
771
231190
protease
140.0
120.0
100.0
80.0
60.0
40.0
20.0Pe
rc
en
ta
ge
 o
f u
np
ro
ce
ss
ed
 C
A
0.0
Wild type
***
***
***
**
W23A A77P A78V L189F L189I L189P
A B
C
Fig. 2. Cleavage of wild-type and mutant HIV-1 CA proteins by HIV-1 PR. (A) Representative SDS/PAGE of the digested CA proteins.
Recombinant CA proteins were incubated with (+) or without () HIV-1 PR at 37 °C for 4 h at pH 5.5; then the reaction mixture was
analyzed by SDS/PAGE. M denotes the molecular weight marker (Precision Plus Protein Dual Xtra Standard). (B) Schematic representation
of proteolytic fragments produced by the proteolytic cleavage. Modified cleavage sites are marked by green arrows and missed cleavages
contributing to the appearance of each fragments are represented by red crosses. Only those fragments are indicated, which have already
been separated and identified previously [12]. (C) Comparison of unprocessed CA amount after proteolytic digestion. Values were calculated
using three independent proteolytic digestion experiments, as described in Materials and methods. Amounts of uncleaved CA after
proteolytic cleavage were quantified by scanning the band densities in the gels and were calculated as percentage of total CA proteins
(incubated without HIV-1 PR). The percentage of proteolytic cleavage for the wild-type was arbitrarily set at 100%. Error bars represent
SD (n = 3). ** P < 0.01, *** P < 0.001.
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Cleavage site mutations affect the secondary
structure of HIV-1 capsid protein
To predict the effect of cleavage site mutations on the
overall CA structure, we have examined the secondary
structure of the proteins using CD spectroscopy. The
molecular ellipticities of the spectra of the proteins
were examined in the range of 180–300 nm, as indi-
cated in Fig. 3. The spectra of mutant CA proteins
were compared to that of the wild-type CA. CD spec-
tra were analyzed by the CDSSTR analysis program;
results are summarized in Table 1. These spectra were
measured at pH 7.5 in which the CA protein maintains
its structural integrity [28,59].
The spectrum of the wild-type CA protein showed
positive ellipticity with a maximum at 190 nm, intense
negative ellipticity with a distinct minimum at 208 nm,
and a shoulder at 220 nm. The crossover point for the
spectra was at 200 nm (Fig. 3). The distribution of the
secondary structural elements is in good agreement
with results published previously for the His6-tagged
CA at pH 7.5 [25,26,28,55], and also with the predic-
tions made from the amino acid sequence of the wild-
type protein (Table 1). The spectra of A78V and
L189F mutants showed similar features to that of the
wild-type, indicating that these proteins have the same
distribution of secondary structural elements (Table 1).
The spectrum of L189I mutant also exhibited similar
features with a higher maximum at 191 nm, suggesting
that its structure only slightly differs from that of the
wild-type protein in its a-helix ratio (Fig. 3). The spec-
tra of the W23A, A77P, and L189P mutants exhibited
several different features compared to that of the wild-
type, such as highly reduced positive and negative
ellipticity and altered crossover points of the curves,
indicating the variable distribution of secondary struc-
tures (Fig. 3).
In summary, based on the results of CD, the sec-
ondary structure of the A78V, L189F, and L189I
mutants show only slight differences and closely
resemble that of the wild-type (Table 1). On the other
hand, W23A and A77P mutants show more pro-
nounced changes in the percentage of secondary struc-
tural elements, the structure of L189P mutant capsid
proteins highly deviated from that of the highly a-heli-
cal wild-type (Table 1).
Predicted effects of mutations were generally in
good agreement with results obtained from CD mea-
surements. Remarkable alterations predicted for the
structures of A77P and L189P mutant capsid proteins
were confirmed by CD measurements. Predicted effects
of A78V, L189F, and L189I mutations corresponded
well with the experimentally determined effects, and
while the distribution of secondary structural elements
in L189I mutant closely resembles that of the wild-type
CA, the A78V and the L189F mutants show only
minor differences compared to the wild-type protein.
Mutant capsid proteins W23A, A77P, and L189I
are more sensitive to tryptic digestion, while
A78V, L189F, and L189P mutants showed similar
tryptic susceptibility to that of the wild-type CA
Previous experiments on HIV-1 CA proteins suggested
that regions exposed to tryptic digestion are crucial for
protein multimerization, and altered proteolytic
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Fig. 3. Circular dichroic spectra of recombinant HIV-1 CA protein
and its mutants in the far-UV region at pH 7.5. The pathlength of
cuvette was 0.02 cm.
Table 1. Secondary structural organization of the wild-type and mutant HIV-1 capsid proteins at pH 7.5. Percentage of secondary structural
elements was determined based on the results of circular dichroism spectroscopic analysis. Values are indicated based on the crystal
structure of wild-type HIV-1 capsid protein (3NTE.pdb) and the result of secondary structure prediction (SOPMA), as well.
Crystal structure Sec.struct. prediction
CD spectroscopy
Wild-type Wild-type Wild-type W23A A77P A78V L189F L189I L189P
a-helix 57 52 48 31 31 48 48 53 17
b-strand 3 11 12 19 18 11 11 11 27
Turn 10 8 15 20 21 16 16 13 22
Unordered 30 29 25 30 30 25 25 23 34
7FEBS Open Bio (2016) ª 2016 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
F. Toth et al. Studies on internal HIV-1 capsid cleavage site mutations
susceptibility to trypsin may result in the formation of
CA oligomers that form structures similar to aberrant
core structures in vitro [60].
The accessibility of tryptic cleavage sites was also
studied to assess structural differences between wild-
type and mutant CA proteins. Equal amount of pro-
teins were subjected to limited proteolysis with trypsin
at the same neutral pH (pH 7.5) that was used for CD
spectroscopy, tryptic digestion was then followed by
SDS/PAGE analysis (Fig. 4).
In case of the CA proteins bearing the A78V,
L189F, or L189P mutations the efficiency of prote-
olytic digestion was found to be similar to that of the
wild-type, no significant difference was observed
(Fig. 4). The results indicate that these mutations led
to only moderate changes of the protein multimeriza-
tion. However, in case of the W23A, A77P, and L189I
mutants the percentage of the uncleaved CA showed
significant reduction (Fig. 4). Based on these results,
we can conclude that the W23A, A77P, and L189I
mutant proteins are more sensitive to trypsin, com-
pared to the wild-type capsid protein. Therefore, it is
expected that these mutant proteins could form aber-
rant core structures.
Mutant HIV-1 CA proteins with deviation in their
secondary structure are still able to bind human
cyclophilin A in vitro
The binding of CypA to the capsid protein is crucial
for the proper decapsidation process in the early phase
of infection. We have tested whether or not mutations
of CA protein may affect the CA-CypA interaction,
and studied the binding efficiency in vitro. Purified
His6-HIVCA and GST-CypA proteins were subjected
to a His6-HIVCA pull-down assay followed by analy-
sis of the eluted complexes by SDS/PAGE (Fig. 5A).
The amount of CypA associated with the W23A,
A78V, L189F, L189I, and L189P mutants did not
change significantly, while A77P mutant showed a
highly reduced CypA binding ability compared to that
of the wild-type CA protein (Fig. 5B).
Based on these results, the introduced mutations
(with the exception of A77P) leading to changes in the
secondary structural organization (Table 1) did not
affect the CypA-binding ability of CA protein. The
CypA-binding region of CA protein is located in an
exposed loop at the protein surface [26], changes of
the secondary structure in a different part of the pro-
tein (Table 1, Fig. 3) may not affect the conformation
or relative position of this flexible loop, and therefore,
do not alter the interactions between the CypA and
the binding loop of CA protein.
Discussion
Our goal in this study was to introduce mutations into
the P1 and P10 positions of internal HIV-1 CA protein
cleavage sites to either enhance or block cleavability at
a given site. Therefore, we have expressed and purified
the wild-type and modified HIV-1 CA proteins
(W23A, A77P, A78V, L189F, L189P, and L189I). Our
aim was to identify appropriate candidates to be intro-
duced into the viral genomes to study the role of CA
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processing in the early phase of HIV-1 infection, or in
lentivirus-mediated gene transfers. Proteolysis at the
cleavage sites containing W23A was substantially
accelerated, leading to enhanced CA degradation. The
A78V and L189F mutations also accelerated process-
ing at the mutated sites, but with lack of enhanced or
even decreased degradation, respectively. On the other
hand, A77P and L189P mutations caused inhibition of
processing at the mutated sites, resulting in decreased
CA degradation.
Cleavage of the protein by HIV-1 PR was carried
out at pH 5.5, which corresponds to the pH of the
endosomes [61] where the multimeric capsid will disas-
semble into monomers with structures altered to the
‘molten globule’ state [28,59]. This structure allows the
binding of the PR to the cleavage sites which are nor-
mally hidden in the helical parts of the protein. Aside
from the cleavage of the CA protein at acidic pH, it
was necessary to clarify whether the mutations affect
the structure of CA at a pH where it has been found
to be resistant to proteolysis. Changes in the protein
structure may contribute to the alteration of prote-
olytic processing and may even have a major effect on
the stability of the core, which affects the infectivity of
the virus, as well [5].
We have predicted the effects of the mutations, and
besides the in silico analysis, we determined the sec-
ondary structural organization of the recombinant
proteins by CD spectroscopy. The results of our pre-
dictions were in good agreement with results obtained
from CD measurements. The A77P and L189P
mutants were predicted to have a highly destabilizing
effect on the protein structure, in line with the fact
that proline is known to be a helix-breaker amino acid
residue. The A78V, L189F, and L189I mutations were
predicted to be neutral (L189I) or slightly destabiliz-
ing. These predictions were confirmed by CD measure-
ments: the secondary structure of A77P and L189P
mutant capsid proteins showed remarkable alterations,
while only slight deviations of the secondary structures
were determined in case of A78V and L189F mutants,
moreover, the distribution of secondary structural ele-
ments in L189I mutant closely resembled that of the
wild-type capsid protein. The only exception is the
W23A mutation, which was predicted to have only a
slightly destabilizing effect, CD measurement, how-
ever, detected remarkable changes in the secondary
structure of this mutant protein. Trp23 has been found
to be a conserved hydrophobic amino acid [2–4], so
this might be the main reason behind the altered sec-
ondary structure.
Previous experiments on HIV-1 CA proteins sug-
gested that regions exposed to tryptic digestion are
crucial for the protein multimerization, in addition,
altered proteolytic susceptibility to trypsin may result
in CA oligomers which form structures similar to
aberrant core structures in vitro [55]. The accessibility
of trypsin cleavage sites was also used to assess struc-
tural differences in the structure of CA. We have
found that the proteolytic susceptibility to trypsin did
not change significantly in case of the A78V, L189F,
and L189P mutants, while the W23A, A77P, and
L189I mutants proved to be more prone to tryptic
processing. In case of the L189F, W23A, A77P, and
L189I mutants, these results are in agreement with
results obtained from in silico analysis and CD mea-
surements.
The importance of interaction between CA and
CypA in the early phase of the replication cycle has
been proved in several experiments [35,40,62], and
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observations from these experiments led to the hypoth-
esis that CypA plays a role in the uncoating mecha-
nism as well [63]. Our results showed that CypA
binding ability of W23A, A78V, L189F, L189I, and
L189P mutants did not change significantly, while the
A77P mutant showed a remarkable reduction in CypA
binding. This was an unexpected result as A77P falls
outside of the Cyp binding region.
Besides CypA, other cellular proteins like CPSF6,
RanBP2, and TNPO3 have also been shown to inter-
act with HIV-1 CA and are able to influence virion
infectivity, but these proteins do not incorporate into
the virion [33]. The binding site of these proteins
appear to be a conserved capsid interface region
formed by surface residues (N57, M66, Q67, K70,
N74, and T107) of the NTD [64]. While these residues
are not mutated in our study, diminished interactions
with the above mentioned proteins and therefore mod-
ulation of the nuclear entry of the viruses carrying the
cleavage site mutations cannot be excluded.
Our results indicate that certain modifications of the
main proteolytic cleavage sites of the HIV-1 CA protein
could affect not only the proteolytic susceptibility by
the HIV-1 PR but also the secondary structure, tryptic
susceptibility, or CypA-binding ability of the mono-
meric CA as well. While W23A, A77P, and L189P
mutations can effectively modify the proteolytic
susceptibility of the CA; along with the so far observed
structural alterations, they are not suitable for our goal.
Based on the experiments performed so far, we can
conclude that the L189F mutant remains structurally
unchanged; hence, it may be the best candidate for use
in experiments affecting the action of HIV-1 PR without
causing structural alterations in the structure of the CA.
It should be noted, that due to the multiple functions of
CA, it appears to be extremely difficult to change its
sequence in such a way that would influence only one
feature of the protein, such as proteolytic susceptibility.
Importantly, a recent study verified the extreme genetic
fragility of HIV-1 CA [65].
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